Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma
Clinical trial NCT01290887 · TERMINATED
Trial details
- NCT number
- NCT01290887
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2011-06-01
- Primary completion
- 2015-01-01
- Enrollment
- 1052
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.